- Home
- GMAB vs POOL Comparison
GMAB vs POOL Comparison
Compare GMAB & POOL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMAB
- POOL
- Stock Information
- Founded
- GMAB 1999
- POOL 1993
- Country
- GMAB Denmark
- POOL United States
- Employees
- GMAB N/A
- POOL N/A
- Industry
- GMAB Biotechnology: Pharmaceutical Preparations
- POOL Industrial Specialties
- Sector
- GMAB Health Care
- POOL Consumer Discretionary
- Exchange
- GMAB Nasdaq
- POOL Nasdaq
- Market Cap
- GMAB 15.0B
- POOL 13.8B
- IPO Year
- GMAB N/A
- POOL 1995
- Fundamental
- Price
- GMAB $20.31
- POOL $349.04
- Analyst Decision
- GMAB Buy
- POOL Hold
- Analyst Count
- GMAB 8
- POOL 8
- Target Price
- GMAB $43.00
- POOL $369.25
- AVG Volume (30 Days)
- GMAB 1.2M
- POOL 363.6K
- Earning Date
- GMAB 02-12-2025
- POOL 02-20-2025
- Dividend Yield
- GMAB N/A
- POOL 1.38%
- EPS Growth
- GMAB 14.35
- POOL N/A
- EPS
- GMAB 10.80
- POOL 11.61
- Revenue
- GMAB $2,967,926,227.00
- POOL $5,326,524,000.00
- Revenue This Year
- GMAB $30.31
- POOL N/A
- Revenue Next Year
- GMAB $16.49
- POOL $3.90
- P/E Ratio
- GMAB $18.44
- POOL $30.06
- Revenue Growth
- GMAB 17.75
- POOL N/A
- 52 Week Low
- GMAB $19.85
- POOL $293.51
- 52 Week High
- GMAB $32.88
- POOL $422.73
- Technical
- Relative Strength Index (RSI)
- GMAB 36.70
- POOL 38.15
- Support Level
- GMAB $19.99
- POOL $340.00
- Resistance Level
- GMAB $21.03
- POOL $380.82
- Average True Range (ATR)
- GMAB 0.38
- POOL 8.16
- MACD
- GMAB -0.07
- POOL -3.71
- Stochastic Oscillator
- GMAB 18.55
- POOL 22.15
About GMAB Genmab A/S ADS
Genmab AS is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
About POOL Pool Corporation
Pool Corp distributes swimming pool supplies and related products. It sells national-brand and private-label products to approximately 120000 customers. The products include non-discretionary pool-maintenance products, like chemicals and replacement parts, as well as pool equipment, like packaged pools (kits to build swimming pools), cleaners, filters, heaters, pumps, and lights. Customers include pool builders and remodelers, independent retail stores, and pool repair and service companies.